While the three approved PARP inhibitors, Olaparib (Lynparza), Niraparib (Zejula), and Rucaparib (Rubraca), have been shown to be beneficial for many patients at all stages of ovarian cancer, they come with a risk of side effects that women should consider when making their treatment choices. We spoke to Dr. Rebecca Arend, a Gynecologic Oncologist at the University of Alabama at Birmingham, to discuss the side effects of PARP inhibitors and what patients can expect when taking them.
According to Dr. Arend, women are likely to experience some initial side effects in the first few months after treatment, including:
- Nausea
- Stomach Cramps
- Fatigue, which is typically the most severe symptom
If women can get through the first two months of treatment, however, these side effects typically subside, says Dr. Arend. “What we’ve found is that if you can get through the first two months of being on maintenance therapy…then you actually start to feel better,” says Arend. Physicians aren’t clear on exactly why this improvement generally occurs. According to Arend, “we don’t know for sure–is it that women are becoming more used to it as their sort of [sic] pace of living? Or is it that their fatigue really goes away?” In any case, women typically start feeling better after two months.
Other possible sides effects that are less common include hypertension, heart palpitations and bone marrow suppression.
Patients should take into account multiple factors when deciding on which PARP inhibitor to choose, says Arend, as there aren’t hard and fast rules. These factors include:
- Insurance Coverage–Which drug does your insurance cover the most? Which is best for your financial situation?
- Disease Progression–One drug may be best for you depending on the stage of your cancer treatment.
- Sensitivity to Platinum-Based Chemo–Have you responded well to chemotherapy? That can help determine which inhibitor may be best for you.
Out of the three PARP inhibitors, oncologists are most comfortable with Olaparib, but that’s simply because of timing, says Dr. Arend. “We probably have the most experience with Olaparib, just because that one was the first one that was FDA-approved. So a lot of us have used [Olaparib] in our patients for the longest amount of time.” Olaparib was approved by the FDA for use in ovarian cancer patients in December of 2014. Nonetheless, Dr. Arend makes clear that all three have virtually the same side effects, so a decision will come down to a conversation with your personal doctor.
Learn more about SurvivorNet's rigorous medical review process.
Dr. Rebecca Arend is an Associate Scientist at the University of Alabama-Birmingham (UAB) Comprehensive Cancer Center Experimental Therapeutics Program. Read More
While the three approved PARP inhibitors, Olaparib (Lynparza), Niraparib (Zejula), and Rucaparib (Rubraca), have been shown to be beneficial for many patients at all stages of ovarian cancer, they come with a risk of side effects that women should consider when making their treatment choices. We spoke to Dr. Rebecca Arend, a Gynecologic Oncologist at the University of Alabama at Birmingham, to discuss the side effects of PARP inhibitors and what patients can expect when taking them.
According to Dr. Arend, women are likely to experience some initial side effects in the first few months after treatment, including:
- Nausea
- Stomach Cramps
- Fatigue, which is typically the most severe symptom
Read More
If women can get through the first two months of treatment, however, these side effects typically subside, says Dr. Arend. “What we’ve found is that if you can get through the first two months of being on maintenance therapy…then you actually start to feel better,” says Arend. Physicians aren’t clear on exactly why this improvement generally occurs. According to Arend, “we don’t know for sure–is it that women are becoming more used to it as their sort of [sic] pace of living? Or is it that their fatigue really goes away?” In any case, women typically start feeling better after two months.
Other possible sides effects that are less common include hypertension, heart palpitations and bone marrow suppression.
Patients should take into account multiple factors when deciding on which PARP inhibitor to choose, says Arend, as there aren’t hard and fast rules. These factors include:
- Insurance Coverage–Which drug does your insurance cover the most? Which is best for your financial situation?
- Disease Progression–One drug may be best for you depending on the stage of your cancer treatment.
- Sensitivity to Platinum-Based Chemo–Have you responded well to chemotherapy? That can help determine which inhibitor may be best for you.
Out of the three PARP inhibitors, oncologists are most comfortable with Olaparib, but that’s simply because of timing, says Dr. Arend. “We probably have the most experience with Olaparib, just because that one was the first one that was FDA-approved. So a lot of us have used [Olaparib] in our patients for the longest amount of time.” Olaparib was approved by the FDA for use in ovarian cancer patients in December of 2014. Nonetheless, Dr. Arend makes clear that all three have virtually the same side effects, so a decision will come down to a conversation with your personal doctor.
Learn more about SurvivorNet's rigorous medical review process.
Dr. Rebecca Arend is an Associate Scientist at the University of Alabama-Birmingham (UAB) Comprehensive Cancer Center Experimental Therapeutics Program. Read More
